124I-FIAU Imaging in EBV and KSHV Associated Cancers (NCT00982449) | Clinical Trial Compass
CompletedNot Applicable
124I-FIAU Imaging in EBV and KSHV Associated Cancers
United States12 participantsStarted 2010-12
Plain-language summary
This research is being done to determine whether viral thymidine kinase (TK) expression in Epstein-Barr virus (EBV) and Kaposi's sarcoma herpesvirus (KSHV) virus-associated tumors is sufficient to image.
Who can participate
Age range18 Years – 75 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Age 18 years or older.
✓. EBV-positive or KSHV-associated malignancy, including but not limited to:
✓. Measurable disease (at least one lesion measuring \> 2 cm in longest axis).
✓. ECOG performance status of 0, 1, or 2.
✓. Patients must be able to lie flat for at least 60 minutes and fit on PET-CT scanner.
✓. For post-therapy imaging with FIAU-PET, treatment with standard or investigational agents that can potentially activate herpesvirus TK, including but not limited to the following. Concurrent radiation therapy is permissible:
✓. AST and ALT \< 3 X upper limit of normal, unless attributed to tumor, obtained within 2 weeks prior to registration.
✓. Serum creatinine \< 2.0 mg/dL, within 2 weeks prior to registration.
Exclusion criteria
✕. End-stage liver disease unrelated to tumor.
✕. Known active or chronic hepatitis B or hepatitis C infection.
To evaluate the potential for enzymatic targeting as evidenced by the ability to image 124I-FIAU tracer uptake in tumor at baseline and following chemotherapy or biologic therapy with agents that may induce viral TK activation.
Timeframe: Baseline, Days 1-3 post chemo
Trial details
NCT IDNCT00982449
SponsorSidney Kimmel Comprehensive Cancer Center at Johns Hopkins